Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01230827 · ClinicalTrials.gov registry record · Phase 3
A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)
A Phase 3 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 3
- Development phase
- 173
- Enrollment target
NCT01230827 is a Phase 3 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 173 participants.
The verdict
NCT01230827, a Phase 3 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 173 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of golimumab (CNTO 148) in patients who have active juvenile idiopathic arthritis (JIA) and at least 5 joints with active arthritis that have poor response to methotrexate.
Interventions
- DRUG Placebo
- DRUG Methotrexate
- DRUG CNTO 148 (Golimumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2010-12 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01230827
The ClinicalTrials.gov registry entry for NCT01230827 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01230827 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01230827 about?
NCT01230827 is a clinical study titled "A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)". The purpose of this study is to evaluate the efficacy and safety of golimumab (CNTO 148) in patients who have active juvenile idiopathic arthritis (JIA) and at least 5 joints with active arthritis that have poor response to methotrexate.
What is the current status of trial NCT01230827?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 173 participants. The study started on 2010-12. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01230827?
The interventions under investigation include: Placebo (DRUG), Methotrexate (DRUG), CNTO 148 (Golimumab) (DRUG).
Who is sponsoring clinical trial NCT01230827?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.